5.33
price down icon3.09%   -0.17
after-market After Hours: 5.33
loading
Precision Biosciences Inc stock is traded at $5.33, with a volume of 69,382. It is down -3.09% in the last 24 hours and up +4.72% over the past month. Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$5.50
Open:
$5.49
24h Volume:
69,382
Relative Volume:
0.46
Market Cap:
$54.12M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-8.0758
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+6.18%
1M Performance:
+4.72%
6M Performance:
-36.32%
1Y Performance:
-45.16%
1-Day Range:
Value
$5.16
$5.6761
1-Week Range:
Value
$4.95
$5.75
52-Week Range:
Value
$3.61
$13.44

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Name
Precision Biosciences Inc
Name
Phone
919-314-5512
Name
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Employee
108
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
DTIL's Discussions on Twitter

Compare DTIL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DTIL
Precision Biosciences Inc
5.33 54.12M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-10-25 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-30-24 Initiated Guggenheim Buy
Jun-17-22 Initiated BMO Capital Markets Outperform
Jun-09-22 Downgrade William Blair Outperform → Mkt Perform
Jul-27-20 Resumed BTIG Research Buy
Apr-03-20 Downgrade Goldman Buy → Neutral
Mar-05-20 Initiated Stifel Buy
Feb-25-20 Initiated William Blair Outperform
Aug-09-19 Initiated BTIG Research Buy
Jul-16-19 Initiated H.C. Wainwright Buy
Apr-22-19 Initiated Barclays Overweight
Apr-22-19 Initiated Goldman Buy
Apr-22-19 Initiated JP Morgan Overweight
Apr-22-19 Initiated Jefferies Buy
View All

Precision Biosciences Inc Stock (DTIL) Latest News

pulisher
Apr 23, 2025

Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView

Apr 16, 2025
pulisher
Apr 16, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Gene Editing Treatment for Hepatitis B Wins FDA Fast Track Status - Stock Titan

Apr 15, 2025
pulisher
Apr 04, 2025

SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow

Apr 04, 2025
pulisher
Apr 01, 2025

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - 01net

Apr 01, 2025
pulisher
Apr 01, 2025

Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan

Apr 01, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer

Mar 27, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Positive 2024 Financial Results - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - CRISPR Medicine News

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Precision BioSciences Inc Q4 Sales Decline - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Precision Biosciences CEO sells $5,359 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire

Mar 25, 2025
pulisher
Mar 23, 2025

PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com

Mar 23, 2025
pulisher
Mar 21, 2025

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace

Mar 21, 2025

Precision Biosciences Inc Stock (DTIL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Precision Biosciences Inc Stock (DTIL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Brown Melinda
Director
Mar 26 '25
Buy
4.75
1,839
8,735
9,057
Germano Geno J
Director
Mar 25 '25
Buy
5.30
3,250
17,225
11,057
Amoroso Michael
President and CEO
Mar 24 '25
Sale
5.56
964
5,360
109,540
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):